Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Lin

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
The Oncologist|September 5, 2020
Professional Medical Writer Assistance in Oncology Clinical TrialsRamez Kouzy, Joseph Abi Jaoude, Walker Mainwaring, et al.
Cancers|February 25, 2022
Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical TrialsRoshal R Patel, Rose Parisi, Vivek Verma, et al.
BMC Cancer|June 13, 2021
Food and Drug Administration approvals in phase 3 Cancer clinical trialsJoseph Abi Jaoude, Ramez Kouzy, Marc Ghabach, et al.
JNCI Cancer Spectrum|November 23, 2020
Racial and Ethnic Disparities Among Participants in US-Based Phase 3 Randomized Cancer Clinical TrialsStephen R Grant, Timothy A Lin, Austin B Miller, et al.
British Journal of Cancer|August 11, 2025
Bayesian interim analysis and efficiency of phase III randomized trialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|December 10, 2024
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological studyTroy J Kleber, Alexander D Sherry, Andrew J Arifin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Bayesian Interim Analysis and Efficiency of Phase III Randomized TrialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|June 6, 2019
The Trials (and Tribulations) of Complementary and Alternative Medicine in OncologyEthan B Ludmir, Amit Jethanandani, Walker Mainwaring, et al.
Practical Radiation Oncology|July 10, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomasSophie T Melancon, Ethan B Wang, Penny Q Fang, et al.
BMC Cancer|September 24, 2020
Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinomaHesham Elhalawani, Abdallah S R Mohamed, Baher Elgohari, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
The Oncologist|September 5, 2020
Professional Medical Writer Assistance in Oncology Clinical TrialsRamez Kouzy, Joseph Abi Jaoude, Walker Mainwaring, et al.
Cancers|February 25, 2022
Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical TrialsRoshal R Patel, Rose Parisi, Vivek Verma, et al.
BMC Cancer|June 13, 2021
Food and Drug Administration approvals in phase 3 Cancer clinical trialsJoseph Abi Jaoude, Ramez Kouzy, Marc Ghabach, et al.
JNCI Cancer Spectrum|November 23, 2020
Racial and Ethnic Disparities Among Participants in US-Based Phase 3 Randomized Cancer Clinical TrialsStephen R Grant, Timothy A Lin, Austin B Miller, et al.
British Journal of Cancer|August 11, 2025
Bayesian interim analysis and efficiency of phase III randomized trialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|December 10, 2024
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological studyTroy J Kleber, Alexander D Sherry, Andrew J Arifin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Bayesian Interim Analysis and Efficiency of Phase III Randomized TrialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|June 6, 2019
The Trials (and Tribulations) of Complementary and Alternative Medicine in OncologyEthan B Ludmir, Amit Jethanandani, Walker Mainwaring, et al.
Practical Radiation Oncology|July 10, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomasSophie T Melancon, Ethan B Wang, Penny Q Fang, et al.
BMC Cancer|September 24, 2020
Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinomaHesham Elhalawani, Abdallah S R Mohamed, Baher Elgohari, et al.
Pageof 6